Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Amyloidosis Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Medicare Part B: Transthyretin-Mediated Amyloidosis Therapy

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Medicare Part B medical policy governs prior authorization and medical-necessity coverage for Onpattro (patisiran) and Amvuttra (vutrisiran) for eligible adults with transthyretin-mediated amyloidosis, including polyneuropathy and selected amyloid cardiomyopathy indications. It applies to providers treating MVP Health Care Medicare Advantage members under the medical benefit.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Transthyretin-Mediated Amyloidosis Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for Onpattro or Amvuttra when covered under the MVP medical benefit.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Drugs requiring prior authorization under the medical benefit
    6 monthsInitial approval period
    PND < IIIb or FAP 1-2Polyneuropathy severity requirement
    NYHA I-III

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Permitted heart-failure classes
    NYHA IVExcluded heart-failure class

    Coverage Criteria

    Initial Onpattro Therapy

    Onpattro is considered medically necessary for the treatment of polyneuropathy of hATTR amyloidosis in adults when ALL of the following criteria are met:

    ALL of the following

      • ONE of the following

        • Baseline polyneuropathy disability (PND) score is < IIIb.

          See the reference table in Appendix A.

        • Baseline familial amyloid polyneuropathy (FAP) Stage 1 or 2.

          See the reference table in Appendix A.

    • Documentation indicates a biopsy is positive for amyloid deposits, or medical justification is provided for initiating treatment despite a negative biopsy or no biopsy.
    • The medication is prescribed by a neurologist, immunologist, geneticist, or physician who specializes in the treatment of amyloidosis.

    Initial Amvuttra Therapy — hATTR Polyneuropathy

    Amvuttra is considered medically necessary for the treatment of polyneuropathy of hATTR amyloidosis in adults when ALL of the following criteria are met:

    ALL of the following

    • Member has previously failed or has a contraindication to Onpattro.

      Chart notes documenting the failure or contraindication to Onpattro are required.

      • ONE of the following

        • Baseline polyneuropathy disability (PND) score is < IIIb.

          See the reference table in Appendix A.

        • Baseline familial amyloid polyneuropathy (FAP) Stage 1 or 2.

          See the reference table in Appendix A.

    Initial Amvuttra Therapy — Amyloid Cardiomyopathy

    Amvuttra is considered medically necessary for the treatment of wild-type or hereditary transthyretin amyloid cardiomyopathy for reduction of cardiovascular mortality, cardiovascular-related hospitalization, and urgent heart failure visits when ALL of the following criteria are met:

    ALL of the following

    • Chart notes document a failure or contraindication to self-administered medications for the diagnosis.
    • Chart notes document a diagnosis of wild-type or hereditary transthyretin-mediated amyloidosis cardiomyopathy and baseline disease severity.
    • Member has New York Heart Association (NYHA) functional class I to III heart failure.

      Member must not have NYHA class IV disease.

    • For hereditary transthyretin-mediated amyloidosis, the presence of a TTR genotype is confirmed by genetic testing.

    Continuation Therapy

    Continuation therapy for Onpattro or Amvuttra will be approved for up to 6 months when ALL of the following are met:

    ALL of the following

    • Current documentation indicates disease stability or improvement in symptoms.

      Examples include decreased neuropathic pain, improved motor function, improved gait speed, improved quality-of-life assessment, improved ability to perform activities of daily living, increased mBMI, and/or serum TTR levels; for cardiomyopathy, examples include improved quality-of-life assessment and decreased cardiac-related hospitalizations.

    • The requested authorization period does not exceed 6 months.

    Coverage is not provided for age, dose, frequency of dosing, and/or duration of therapy outside FDA-approved package labeling.

    Coverage is not provided for concurrent use of Tegsedi with Amvuttra, Onpattro, or tafamidis.

    Coverage is not provided for concurrent use of Vyndaqel and Vyndamax.

    Coverage is not provided for treatment with Onpattro in members without polyneuropathy symptoms associated with hATTR amyloidosis.

    Coverage is not provided for treatment with Onpattro when the member has a form of amyloidosis that is not due to a genetic mutation in the TTR gene.

    Coverage is not provided for Amvuttra treatment of cardiomyopathy in members with NYHA class IV disease.

    Coding and Authorization Parameters

    Covered HCPCS CodesHCPCSCovered
    J0222Onpattro (patisiran)
    J0225Amvuttra (vutrisiran)
    Baseline PND score
    Qualifying thresholdBaseline PND score < IIIb
    Qualifying stagesStages 0, I, II, and IIIa
    Not qualifyingStage IIIb or Stage IV
    Baseline FAP stage
    Qualifying thresholdBaseline FAP Stage 1 or 2
    Stage 1Unimpaired ambulation; mostly mild sensory, autonomic, or motor neuropathy in the lower limbs
    Stage 2Requires assistance with ambulation; mostly moderate impairment progression in the lower limbs, upper limbs, and trunk

    Provider Actions and Documentation

    Prior Authorization

    Medical-Benefit Prior Authorization Required

    Prior authorization is required under the MVP medical benefit before billing or administering Onpattro or Amvuttra.

    • J0222 — Onpattro (patisiran)
    • J0225 — Amvuttra (vutrisiran)
    Step Therapy

    Document Onpattro Failure or Contraindication

    For Amvuttra treatment of hATTR polyneuropathy, document that the member previously failed Onpattro or has a contraindication to Onpattro before requesting authorization.

    • Include chart notes describing the Onpattro treatment failure or the specific contraindication.
    • This prerequisite applies to Amvuttra polyneuropathy therapy, not to the cardiomyopathy indication.

    Unsupported block type: step_therapyによ?

    Clinical Background

    Hereditary transthyretin amyloidosis (hATTR) is an inherited disease in which abnormal transthyretin protein deposits as amyloid in organs including the liver, peripheral nerves, heart, and kidneys. Peripheral nerve involvement may cause sensory loss, pain, weakness, impaired walking, and immobility. Onpattro and Amvuttra are small interfering RNA therapies that reduce transthyretin production; Amvuttra also has an indication for wild-type or hereditary transthyretin amyloid cardiomyopathy.

    Definitions

    Polyneuropathy Disability (PND) score
    Stage 0No impairment
    Stage ISensory disturbances but preserved walking capability
    Stage IIImpaired walking capability but able to walk without a stick or crutches
    Stage IIIaWalking only with the help of one stick or crutch
    Stage IIIbWalking with the help of two sticks or crutches
    Stage IVConfined to a wheelchair or bedridden
    Familial Amyloid Polyneuropathy (FAP) stage

    Initial Therapy Criteria

    Onpattro Initial Therapy

    Onpattro is considered medically necessary for qualifying adults with hATTR polyneuropathy when all of the following are met.

    Onpattro initial therapy

    • Disease and severity

      • Qualifying baseline severity: Baseline PND score < IIIb or baseline FAP Stage 1 or 2PND < IIIb or FAP Stage 1-2
    • Amyloid confirmation: Biopsy is positive for amyloid deposits, or medical justification is provided for initiating treatment despite a negative biopsy or no biopsy.
    • Prescriber qualification:

    Continuation Criteria

    Continuation of Onpattro or Amvuttra

    Continuation of Onpattro or Amvuttra may be approved for up to 6 months when all of the following are met.

    Clinical response or stability: Current documentation indicates disease stability or improvement.

    For polyneuropathy, evidence may include decreased neuropathic pain, improved motor function, improved gait speed, improved quality of life, improved activities of daily living, increased modified body mass index, and/or serum TTR levels. For cardiomyopathy, evidence may include improved quality of life or decreased cardiac-related hospitalizations.

    Step Therapy Requirements

    StepTreatment indicationRequirement
    1Amvuttra for hATTR polyneuropathyThe member must have previously failed Onpattro or have a documented contraindication to Onpattro. The requirement must be documented in the chart.
    StepTreatment indicationRequirement
    1Amvuttra for wild-type or hereditary transthyretin amyloid cardiomyopathyThe member must have documented failure of or a contraindication to self-administered medications for the diagnosis.
    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Transthyretin-Mediated Amyloidosis Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for Onpattro or Amvuttra when covered under the MVP medical benefit.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Authorization ParametersProvider Actions and DocumentationClinical BackgroundDefinitionsInitial Therapy CriteriaContinuation CriteriaStep Therapy Requirements
    Documentation indicates a biopsy is positive for amyloid deposits, or medical justification is provided for initiating treatment despite a negative biopsy or no biopsy.
  1. Baseline documentation of disease status is submitted, if applicable, such as a 10-meter walk test, quality-of-life assessment, nutritional health assessment or modified body mass index (mBMI), and ability to perform activities of daily living.
  2. The medication is prescribed by a neurologist, immunologist, geneticist, cardiologist, or physician who specializes in the treatment of amyloidosis.
  3. A biopsy is positive for amyloid deposits, or medical justification is provided for initiating treatment despite a negative biopsy or no biopsy.
  4. The medication is prescribed by or in consultation with a geneticist, cardiologist, or physician specializing in the treatment of amyloidosis.
  5. NYHA heart-failure functional class
    Permitted classesNYHA functional class I to III heart failure
    Class I to IIIEligible functional-class range for Amvuttra cardiomyopathy treatment
    Excluded classNYHA class IV disease
    Initial and continuation authorization
    Initial approval6 months
    Extension durationUp to 6 months
    Extension conditionCurrent documentation must indicate disease stability or improvement in symptoms
    Documentation Required

    Onpattro Documentation Requirements

    For Onpattro, submit records confirming all applicable medical-necessity elements: a TTR mutation confirmed by genetic testing; symptomatic hATTR polyneuropathy; baseline PND score below IIIb or FAP Stage 1 or 2; and a biopsy positive for amyloid deposits, or medical justification for treatment despite a negative or absent biopsy.

    • Symptoms may include weakness, sensory loss, decreased motor strength, or decreased gait speed.
    • The prescriber must be a neurologist, immunologist, geneticist, or physician specializing in amyloidosis treatment.
    • Include relevant genetic, neurologic, pathology, and clinical records.
    Documentation Required

    Amvuttra Polyneuropathy Documentation

    For Amvuttra polyneuropathy therapy, submit documentation of Onpattro failure or contraindication together with the required disease records.

    • TTR mutation confirmed through genetic testing and symptomatic hATTR polyneuropathy.
    • Baseline PND score below IIIb or FAP Stage 1 or 2.
    • Positive amyloid biopsy, or medical justification for treatment despite a negative or absent biopsy.
    • Baseline disease status when applicable, including a 10-meter walk test, quality-of-life assessment, nutritional health assessment or mBMI, and ability to perform activities of daily living.
    • Prescriber must be a neurologist, immunologist, geneticist, cardiologist, or physician specializing in amyloidosis treatment.
    Documentation Required

    Amvuttra Cardiomyopathy Documentation

    For Amvuttra cardiomyopathy therapy, submit records establishing qualifying wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy and the member's baseline disease status.

    • Document NYHA functional class I, II, or III; NYHA class IV disease is not eligible.
    • For hereditary disease, provide TTR genotype confirmation through genetic testing.
    • Provide a positive amyloid biopsy or medical justification for treatment despite a negative or absent biopsy.
    • Document prescribing by or consultation with a geneticist, cardiologist, or physician specializing in amyloidosis treatment.
    • Include the diagnosis, baseline severity, and relevant clinical records.
    Documentation Required

    Continuation Documentation Required

    Initial approval is for 6 months, and continuation requests may be approved for up to 6 months when current records show disease stability or improvement.

    • For polyneuropathy, submit current measures such as neuropathic pain, motor function, gait speed, quality of life, activities of daily living, mBMI, and/or serum TTR levels.
    • For cardiomyopathy, submit current evidence such as quality-of-life assessment and reduced cardiac-related hospitalizations.
    • Include updated clinical assessments supporting continued treatment.
    Denial Risk

    Labeling, Concurrent Therapy, and Indication Exclusions

    Coverage may be denied when treatment falls outside FDA-approved labeling, when prohibited therapies are used concurrently, or when the indication does not meet the policy criteria.

    • Age, dose, dosing frequency, or duration outside FDA-approved package labeling is excluded.
    • Do not use Tegsedi concurrently with Amvuttra, Onpattro, or tafamidis.
    • Do not use Vyndaqel concurrently with Vyndamax.
    • Onpattro is not covered for hATTR without polyneuropathy symptoms or for amyloidosis not caused by a TTR genetic mutation.
    Documentation Required

    Amvuttra Polyneuropathy Prerequisites

    Before requesting Amvuttra for hATTR polyneuropathy, verify and submit the complete prerequisite package rather than relying on the medication request alone.

    • Document prior Onpattro failure or contraindication.
    • Confirm the TTR mutation through genetic testing and document symptomatic polyneuropathy with PND below IIIb or FAP Stage 1 or 2.
    • Provide biopsy confirmation or a medical justification for treatment without positive biopsy findings.
    • Include baseline functional, nutritional, quality-of-life, and activities-of-daily-living measures when applicable.
    Documentation Required

    Amvuttra Cardiomyopathy Prerequisites

    Before requesting Amvuttra for cardiomyopathy, verify that the member has qualifying transthyretin amyloid cardiomyopathy and has failed or cannot use self-administered medication therapy.

    • Document wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy and baseline disease severity.
    • Confirm NYHA functional class I to III; NYHA class IV disease is excluded.
    • For hereditary disease, provide genetically confirmed TTR genotype; also provide biopsy confirmation or justification for treatment without a positive biopsy.
    • Include the required medication history and specialist prescribing or consultation.
    Stage 0No symptoms of sensory or motor neuropathy
    Stage 1Unimpaired ambulation; mostly mild sensory, autonomic, or motor neuropathy in lower limbs
    Stage 2Requires assistance with ambulation; mostly moderate impairment progression in lower limbs, upper limbs, and trunk
    Stage 3Confined to wheelchair or bedridden; severe sensory, autonomic, and motor involvement of all limbs
    siRNA
    DefinitionA small interfering RNA (siRNA) is a very short piece of synthetic genetic material
    MechanismDesigned to attach to and block the genetic material of the cell responsible for producing transthyretin
    ResultReduces production of defective transthyretin, thereby reducing amyloid formation and relieving hATTR amyloidosis symptoms
    The medication is prescribed by a neurologist, immunologist, geneticist, or physician who specializes in the treatment of amyloidosis.

    Amvuttra Initial Therapy for hATTR Polyneuropathy

    Amvuttra is considered medically necessary for qualifying adults with hATTR polyneuropathy after Onpattro failure or contraindication when all of the following are met.

    Amvuttra polyneuropathy initial therapy

    • Prior therapy: The member previously failed Onpattro or has a contraindication to Onpattro, documented in chart notes.
    • Disease and severity

      • Qualifying baseline severity: Baseline PND score < IIIb or baseline FAP Stage 1 or 2PND < IIIb or FAP Stage 1-2
    • Amyloid confirmation: Biopsy is positive for amyloid deposits, or medical justification is provided for initiating treatment despite a negative biopsy or no biopsy.
    • Prescriber qualification: The medication is prescribed by a neurologist, immunologist, geneticist, cardiologist, or physician who specializes in the treatment of amyloidosis.

    Amvuttra Initial Therapy for Amyloid Cardiomyopathy

    Amvuttra is considered medically necessary for qualifying wild-type or hereditary transthyretin amyloid cardiomyopathy when all of the following are met.

    Amvuttra cardiomyopathy initial therapy

    • Prior therapy: Chart notes document failure or contraindication to self-administered medications for the diagnosis.
    • Diagnosis and severity: Chart notes document wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy and baseline disease severity.
    • Heart-failure status: The member has NYHA functional class I to III heart failure.NYHA I-III

      NYHA class IV disease is excluded.

    • Genetic confirmation when hereditary: For hereditary transthyretin-mediated amyloidosis, the TTR genotype is confirmed by genetic testing.
    • Amyloid confirmation: Biopsy is positive for amyloid deposits, or medical justification is provided for initiating treatment despite a negative biopsy or no biopsy.
    • Prescriber qualification: The medication is prescribed by or in consultation with a geneticist, cardiologist, or physician specializing in the treatment of amyloidosis.